SU-F-J-67: Dosimetric Changes During Radiotherapy in Lung Cancer Patients with Atelectasis
- Virginia Commonwealth University, Richmond, VA (United States)
- University of Iowa, Iowa City, IA (United States)
Purpose: Large geometric changes which occur during thoracic radiotherapy alter normal anatomy and target position and may induce clinically important dose changes. This study investigates variation of organ-at-risk (OAR) dose caused by atelectasis resolution during radiotherapy. Methods: 3D IMRT treatment plans were obtained for 14 non-small-cell lung cancer patients. Dose of the clinical plan was recalculated on a baseline scan in which lung was collapsed and on a midtreatment scan in which lung re-aeration had occurred. The changes in OAR doses were compared between the two time points. RTOG-0617 and inhouse dose-volume constraints were chosen for investigation and included spinal cord, esophagus, heart, and healthy lung. Results: 17 dose metrics were evaluated. The mean (SD) of change in mean lung dose, from baseline to mid-treatment (average taken across all patients), was 0.2 Gy (2.2 Gy) and ranged from −3.2 Gy to 6.0 Gy. 50% of patients experienced relative changes in mean lung dose of greater than 5% of baseline value. The mean (SD) of changes in heart V{sub 40}, V{sub 45}, and V{sup 60} were 3.2% (3.4%), 3.0% (2.9%), and 1.4% (2.1%), respectively, and were significant for the study cohort (Wilcoxon signed-rank test, p=0.0107 for V{sub 40}, p=0.0052 for V{sub 45}, and p= 0.0353 for V{sub 60}. Ranges in changes of Heart V{sub 40}, V{sub 45}, and V{sub 60} were −1.9% to 8.6%, −1.7% to 7.5%, and −2.1% to 4.5%, respectively. The mean (SD) of changes in Esophagus PRV Dmean and V{sub 60} were 0.3 Gy (3.3 Gy) and 0.8% (7.7%), respectively, and ranged from −4.8 Gy to 6.8 Gy for Dmean and −15.2% to 14.6% for V{sub 60}. Conclusion: Patients with atelectasis present at the start of radiotherapy experience significant increases in heart dose. Substantial increases in mean lung dose also occur in a subset of patients. This work supported by the National Cancer Institute of National Institutes of Health under Award Number R01CA166119. Disclosures: Phillips Medical systems (Hugo, Weiss), National Institutes of Health (Hugo, Weiss, Christensen), and Roger Koch (Christensen) support, UpToDate (Weiss) royalties, and Varian Medical Systems (Hugo, Weiss) license. No potential conflicts of interest.
- OSTI ID:
- 22632197
- Journal Information:
- Medical Physics, Vol. 43, Issue 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA); ISSN 0094-2405
- Country of Publication:
- United States
- Language:
- English
Similar Records
Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes From a Phase II Study
A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization